157 related articles for article (PubMed ID: 31815559)
1. The importance of targeting HIV reservoirs: preclinical insights on current and potential therapeutic opportunities.
Cory TJ
Expert Opin Ther Targets; 2019 Dec; 23(12):987-989. PubMed ID: 31815559
[No Abstract] [Full Text] [Related]
2. Insights into HIV-1 capsid inhibitors in preclinical and early clinical development as antiretroviral agents.
Cevik M; Orkin C
Expert Opin Investig Drugs; 2019 Dec; 28(12):1021-1024. PubMed ID: 31738620
[No Abstract] [Full Text] [Related]
3. The mouse viral outgrowth assay: avatars for the detection of HIV-1 reservoirs.
Metcalf Pate KA; Blankson JN
Retrovirology; 2017 Nov; 14(1):52. PubMed ID: 29157283
[TBL] [Abstract][Full Text] [Related]
4. HIV "shock and kill" therapy: In need of revision.
Abner E; Jordan A
Antiviral Res; 2019 Jun; 166():19-34. PubMed ID: 30914265
[TBL] [Abstract][Full Text] [Related]
5. Which therapeutic strategy will achieve a cure for HIV-1?
Cillo AR; Mellors JW
Curr Opin Virol; 2016 Jun; 18():14-9. PubMed ID: 26985878
[TBL] [Abstract][Full Text] [Related]
6. Should patients with drug-resistant HIV-1 continue to receive antiretroviral therapy?
Frenkel LM; Mullins JI
N Engl J Med; 2001 Feb; 344(7):520-2. PubMed ID: 11172196
[No Abstract] [Full Text] [Related]
7. Effective inhibition of HIV-1 isolated from patients with acute primary HIV-1 infection by aminooxypentane-RANTES.
Rusconi S; Merrill DP; La Seta-Catamancio S; Citterio P; Offord RE; Hirsch MS
AIDS; 1999 Jun; 13(9):1144-5. PubMed ID: 10397549
[No Abstract] [Full Text] [Related]
8. Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection.
Turriziani O; Andreoni M; Antonelli G
Clin Microbiol Infect; 2010 Oct; 16(10):1518-24. PubMed ID: 20673260
[TBL] [Abstract][Full Text] [Related]
9. Natural product-derived compounds in HIV suppression, remission, and eradication strategies.
Andersen RJ; Ntie-Kang F; Tietjen I
Antiviral Res; 2018 Oct; 158():63-77. PubMed ID: 30063970
[TBL] [Abstract][Full Text] [Related]
10. Emtricitabine compared with lamivudine may preserve future therapeutic options in HIV-1-infected children.
Frange P; Blanche S; Chaix ML
J Antimicrob Chemother; 2013 Nov; 68(11):2694-5. PubMed ID: 23743089
[No Abstract] [Full Text] [Related]
11. What can we do to reduce the viral reservoir in HIV-1-infected individuals?
Pohlmeyer CW; Walker-Sperling VE; Blankson JN
Future Microbiol; 2016 Jul; 11():839-42. PubMed ID: 27416850
[No Abstract] [Full Text] [Related]
12. Candidate microbicides and their mechanisms of action.
Herrera C; Shattock RJ
Curr Top Microbiol Immunol; 2014; 383():1-25. PubMed ID: 23612992
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment HIV-1 drug resistance in Africa.
Hamers RL; Kityo C; Sigaloff KC; de Wit TF
Lancet Infect Dis; 2013 Jun; 13(6):476. PubMed ID: 23718920
[No Abstract] [Full Text] [Related]
14. Transmission of zidovudine resistant strains of HIV-1: the first wave.
Blower S
AIDS; 2001 Nov; 15(17):2317-8. PubMed ID: 11698706
[No Abstract] [Full Text] [Related]
15. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy.
Schrager LK; D'Souza MP
JAMA; 1998 Jul; 280(1):67-71. PubMed ID: 9660366
[TBL] [Abstract][Full Text] [Related]
16. In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a "Block-and-Lock" Strategy for HIV-1 Treatment.
Kessing CF; Nixon CC; Li C; Tsai P; Takata H; Mousseau G; Ho PT; Honeycutt JB; Fallahi M; Trautmann L; Garcia JV; Valente ST
Cell Rep; 2017 Oct; 21(3):600-611. PubMed ID: 29045830
[TBL] [Abstract][Full Text] [Related]
17. Roundtable report: importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs.
Reddy YS; Kashuba A; Gerber J; Miller V;
AIDS Res Hum Retroviruses; 2003 Mar; 19(3):167-76. PubMed ID: 12689408
[No Abstract] [Full Text] [Related]
18. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
[No Abstract] [Full Text] [Related]
19. Update of the drug resistance mutations in HIV-1: December 2009.
Johnson VA; Brun-Vezinet F; Clotet B; Gunthard HF; Kuritzkes DR; Pillay D; Schapiro JM; Richman DD
Top HIV Med; 2009 Dec; 17(5):138-45. PubMed ID: 20068260
[No Abstract] [Full Text] [Related]
20. Evaluation of the anti-HIV activity of statins.
Moncunill G; Negredo E; Bosch L; Vilarrasa J; Witvrouw M; Llano A; Clotet B; Esté JA
AIDS; 2005 Oct; 19(15):1697-700. PubMed ID: 16184043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
